Key facts
- This page summarizes Yannick Chane-Du Mickael's Form 3 filing for Adagene Inc. (ADAG).
- 0 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 18 Mar 2026, 09:05.
Yannick Chane-Du Mickael - 18 Mar 2026 Form 3 Insider Report for Adagene Inc. (ADAG)
- Reporting relationship
- Chief Strategy Officer
- Issuer ticker
- ADAG
- Reported as of
- 18 Mar 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ Mickael Chane-Du
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Yannick Chane-Du Mickael filed Form 3 for Adagene Inc. (ADAG) on 18 Mar 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002117912
Primary reporting owner
Chane-Du Mickael Yannick
- Relationship
- Chief Strategy Officer
- Address
- 4F, BUILDING C14, NO. 218 XINGHU STREET, SUZHOU JIANGSU, CHINA
- Signature
- /s/ Mickael Chane-Du
- Signature date
- 18 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ADAG
holding
Adagene Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 188,019
- Date
- 18 Mar 2026
- Ownership
- Investment in OT Healthcare Fund I, LLC
ADAG
holding
Adagene Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 279,506
- Date
- 18 Mar 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ADAG
holding
Derivative
Incentive Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 400,000
- Exercise price
- $1.38
- Footnotes
- F1
ADAG
holding
Derivative
Warrants
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Through OT Bio Advisory, LLC
- Underlying class
- Ordinary Shares
- Underlying amount
- 250,000
- Exercise price
- $4.00
ADAG
holding
Derivative
Warrants
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Through OT Bio Advisory, LLC
- Underlying class
- Ordinary Shares
- Underlying amount
- 250,000
- Exercise price
- $4.00
ADAG
holding
Derivative
Incentive Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 400,000
- Exercise price
- $2.03
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
400,000 of time-based stock option granted on 5/13/2025 under the Adagene Inc. 2021 Performance Incentive Plan, and become exercisable with respect to 4-year vesting (25% upon 1st anniversary and monthly vesting thereafter).
Footnote F2
400,000 of performance-based stock option granted on 2/5/2026 under the Adagene Inc. 2021 Performance Incentive Plan, and become exercisable when milestone achieved.